Hollow Brook Wealth Management sold its entire position in Bio-Techne -- 174,677 shares -- during the fourth quarter of 2025, for an estimated $10.7 million based on quarterly average pricing. The ...
TECH gears up for Q3 results with modest revenue growth expected as biotech funding trends and product momentum shape the ...
Techne Corporation, the Minneapolis-based biotechnology company that now does business under the “Bio-Techne” brand, recently announced that it’s investing $10 million CyVek, Inc.—and it might ...
Shares of Bio-Techne Corp. plunged 10.89% to $52.20 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index falling 0.41% to 7,108.40 and Dow ...
Bio-Techne Corporation (NasdaqGS:TECH) is rolling out a new brand architecture centered on three portfolio brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™. The updated structure ...
The DCF model implemented in this article suggests that Bio-Techne is overvalued by 34.53%. Bio-Techne has allocated significant financial resources to capex. Due to these resources, its revenues ...
RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...
Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science research tools, analytical instruments, and diagnostics, today announced ...
Bio-Techne Corp. TECH has recently entered into a distribution agreement with the U.S. Pharmacopeia (“USP”) to sell USP monoclonal antibody (mAb) and recombinant adeno-associated virus (AAV) reference ...
In the latest quarter, 7 analysts provided ratings for Bio-Techne (NASDAQ:TECH), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the ...
Minneapolis-based life sciences firm Bio-Techne Corp. on Wednesday said it’s reached a deal to buy Austin, Texas-based Asuragen for up to $320 million. Under the terms of the deal, Bio-Techne will pay ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results